Michael Benkowitz Sells 10,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $896,950.62. The trade was a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Michael Benkowitz also recently made the following trade(s):

• On Monday, February 3rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $353.64, for a total transaction of $3,536,400.00.
• On Monday, January 27th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $370.71, for a total value of $3,707,100.00.
• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.91, for a total value of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $364.62, for a total value of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $356.68, for a total value of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $361.95, for a total transaction of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded up $0.14 during midday trading on Friday, hitting $370.58. The stock had a trading volume of 209,344 shares, compared to its average volume of 312,203. The company's 50-day simple moving average is $361.93 and its 200 day simple moving average is $358.80. The firm has a market cap of $16.55 billion, a P/E ratio of 16.27, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57. United Therapeutics Co. has a fifty-two week low of $211.61 and a fifty-two week high of $417.82.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in UTHR. Wealthfront Advisers LLC lifted its holdings in United Therapeutics by 2,090,573.5% in the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after buying an additional 18,313,424 shares during the period. Vanguard Group Inc. lifted its holdings in United Therapeutics by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock valued at $1,567,253,000 after buying an additional 32,213 shares during the period. FMR LLC lifted its holdings in United Therapeutics by 36.5% in the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after buying an additional 393,777 shares during the period. Geode Capital Management LLC boosted its position in shares of United Therapeutics by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock worth $401,184,000 after purchasing an additional 44,277 shares during the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of United Therapeutics by 0.8% in the 4th quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock worth $344,176,000 after purchasing an additional 7,710 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on UTHR shares. The Goldman Sachs Group raised their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research note on Friday, November 1st. Argus boosted their price target on United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, January 16th. UBS Group boosted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Finally, LADENBURG THALM/SH SH upped their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $382.08.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.